Browse the evidence

Phentermine/topiramate ER treatment improved glucose regulation, lipid profiles, and decreased blood pressure.

The treatment may enhance metabolic health in obese patients.

Lean mass constituted 25%–39% of total weight lost with incretin agonists: semaglutide (35.2%), tirzepatide (25.4%), and liraglutide (26.8%).

Incretin therapies can lead to significant lean mass loss during weight reduction.

Lifestyle interventions showed comparable proportional lean mass loss (26.2%) to incretin therapies (p = 0.42 for comparison).

Lifestyle interventions can be as effective as incretin therapies in preserving lean mass during weight loss.

Efsubaglutide Alfa showed a preferable tolerability and safety profile.

Efsubaglutide Alfa may be a safer option for weight management compared to other treatments.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.

Discontinuing GLP-1RA treatment leads to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those prescribed semaglutide/tirzepatide.

Practitioners should consider the likelihood of weight regain when discontinuing GLP-1RA therapy.

The proportion of weight regained after discontinuation of GLP-1RA therapy is proportional to the amount originally lost.

Weight loss strategies should account for the likelihood of proportional weight regain after stopping GLP-1RA therapy.

Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions.

Clinicians should inform patients that stopping GLP-1RA may lead to weight regain despite lifestyle efforts.

GLP-1 receptor agonists (semaglutide, liraglutide) significantly improve cardiovascular biomarkers—including hs-CRP, systolic blood pressure, and lipid profiles—independent of glycemic control.

GLP-1 medications like semaglutide do more than just help you lose weight; they directly improve your heart health markers. They significantly lower systemic inflammation (hs-CRP), improve blood vessel function, lower blood pressure, and improve lipid profiles. These benefits happen even if you don't have diabetes, proving the drug protects your blood vessels directly. You should be aware of the slightly increased risk of gallbladder issues due to rapid weight loss, so your doctor will monitor your baseline risk.

GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).

GLP1-RAs may enhance mental health quality of life in this population.

The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.

Practitioners should consider the growing preference for semaglutide in obesity treatment.

The diet beneficially altered microbiota-derived plasma metabolites implicated in chronic non-communicable diseases.

Practitioners may consider the impact of dietary choices on metabolites that influence chronic disease risk.

Regular physical activity boosts host immunity and facilitates a more diverse gut microbiome.

Encouraging regular physical activity can enhance immune function and gut health.

The study suggests reassessing the preoperative withholding guidelines for GLP-1 receptor agonists.

Healthcare providers may need to update their protocols regarding GLP-1 RA use before surgery.

Tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduces Obstructive Sleep Apnea severity (AHI) and improves cardiometabolic biomarkers in patients with moderate-to-severe OSA and obesity, leading to FDA approval for this indication.

If you have moderate-to-severe sleep apnea and obesity, ask your doctor about tirzepatide. It is an FDA-approved treatment that reduces breathing interruptions during sleep and improves heart health markers. It requires weekly injections and lifestyle counseling, but offers a viable alternative or adjunct to CPAP for those struggling with adherence or residual symptoms.

Patients treated with GLP-1 RAs experienced a lower occurrence of sight-threatening complications, including blindness (HR, 0.77; 95% CI, 0.73-0.82).

GLP-1 RAs may help reduce the risk of severe ocular complications in T2D patients.

The mean total costs over 2 years were lower for MBS ($51,794) compared to GLP-1 receptor agonists ($63,483).

MBS may offer a more cost-effective long-term solution for obesity treatment.

GLP-1 RA use was associated with lower medication use (RR, 0.53; 95% CI, 0.46-0.61; P < .001).

GLP-1 RAs may reduce the need for other medications in IIH management.

GLP-1 RA use was associated with reduced headaches (RR, 0.45; 95% CI, 0.35-0.58; P < .001).

GLP-1 RAs may help alleviate headache symptoms in IIH patients.

GLP-1 RA therapy is associated with significant reductions in procedural interventions (RR, 0.44; 95% CI, 0.30-0.63; P < .001).

GLP-1 RAs may reduce the need for surgical or other procedural interventions in IIH management.

Pharmacologic interventions targeting modifiable cardiometabolic risk factors are a reasonable strategy to prevent CVD development and progression of MASLD.

Practitioners should consider pharmacologic interventions for patients with MASLD to mitigate CVD risk.

Resmetirom has shown positive effects regarding CVD risk in the context of MASLD treatment.

Consider resmetirom as a potential treatment option for patients with MASLD at risk for CVD.

Semaglutide treatment resulted in a 17% reduction in new-onset atrial fibrillation (AF) incidence compared to controls.

Semaglutide may be an effective treatment option for reducing the risk of new-onset AF in patients.